- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Pal on RCS in Metastatic Urothelial Carcinoma
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses changes in relative conditional survival in metastatic urothelial carcinoma.
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses a SEER database analysis that explored survival outcomes for patients with metastatic urothelial carcinoma (mUC).
The SEER database incorporates data from about 28% of the US population and is used across several studies to evaluate outcomes. In this specific analysis, changes in relative conditional survival (RCS), a statistical endpoint used to help predict survival, was utilized to determine the efficacy of second- and third-line treatments in mUC.
Treatments used after the frontline setting for patients with mUC are largely based on evidence from phase II trials. Unfortunately, this analysis established that many of these treatments used after the frontline setting do not result in major improvements in RCS, Pal states. This suggests that despite best efforts, these later lines of therapy might not be effecting a real change on the natural history of the disease.
<<<